Chengdu Easton Biopharmaceuticals Hits Day High with 7.05% Surge

Chengdu Easton Biopharmaceuticals Co., Ltd. has experienced a significant uptick in its stock performance, gaining 7.05% on March 27, 2026. The stock reached an intraday high of CNY 68.51, reflecting strong market activity. Over the past week, the company has shown a robust performance, with a 13.8% increase, significantly outperforming the China Shanghai Composite, which declined by 1.09% during the same period. In terms of longer-term performance, Chengdu Easton Biopharmaceuticals has delivered impressive returns, with a 105.77% increase over the past year, compared to the 16.01% rise in the China Shanghai Composite. The company’s market capitalization stands at CNY 11,367 million, positioning it as a midcap player in the pharmaceuticals and biotechnology sector. Financial metrics indicate a solid operational foundation, with the highest operating cash flow recorded at CNY 335.41 million. The company has also seen a decrease in raw material costs by 1.58% year-over-year. Despite a slight decline in profits over the past year, the stock continues to demonstrate strong market performance, underscoring its competitive position within the industry.